Details for Patent: 9,624,250
✉ Email this page to a colleague
Which drugs does patent 9,624,250 protect, and when does it expire?
Patent 9,624,250 protects SIVEXTRO and is included in two NDAs.
This patent has forty-one patent family members in twenty-eight countries.
Summary for Patent: 9,624,250
Title: | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
Abstract: | A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydro- xymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the crystalline form may be used in antibiotics. |
Inventor(s): | Reichenbacher; Katharina (Riehen, CH), Duguid; Robert J. (Glenmont, NY), Ware; Jacqueline A. (Virginia Beach, VA), Phillipson; Douglas (Del Mar, CA) |
Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
Application Number: | 14/959,412 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Process; Dosage form; |
Drugs Protected by US Patent 9,624,250
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA | ⤷ Sign Up | ||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,624,250
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
African Regional IP Organization (ARIPO) | 2987 | ⤷ Sign Up | |||
Australia | 2010210627 | ⤷ Sign Up | |||
Brazil | PI1008829 | ⤷ Sign Up | |||
Canada | 2751392 | ⤷ Sign Up | |||
Chile | 2011001855 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |